RSV vaccine manufacturers vie for market share in second year of vaccinations

Pfizer, GSK and Moderna’s competition to supply new respiratory syncytial virus (RSV) vaccines is on Wall Street’s watch list as the companies will report their earnings later this week.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO